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ABSTRACT 
Background: Joined oral contraception obstructs the 
endogenous ovarian steroid emission that settles the 
hormonal conditions. Progestin dominant, monophasic, 
contraceptives may prompt relapse of estrogen dependent 
infections, for example uterine fibroids and 
endometriosis. 
Objective: The aim of this investigation was to report 
the improvement of uterine fibroids presented to the 
impact of joined oral preventative with progestin 
dominancy. 
Materials and Methods: This randomized controlled 
single blind prospective observational study was carried 
out at Sir Ganga Ram Hospital, Lahore during the period 
from 01.07.2017 to 31.07.2018. Total 258 patients were 
selected for the study, which were randomly partitioned 
into two groups: 194 females with one or various uterine 
fibroids treated minimalistically with monophasic 
hormonal pills containing ethinylestradiol 20mcg and 
gestodene 75mcg were watched for a time of handsome 
period and 64 females in the control gathering.  
Results: In 150 patients (77.31% vs 31.21% of untreated 
controls), relapse or no development was enrolled. In 44 
(22.7%) patients, the span of myoma expanded, monthly 
cycle anomaly and overwhelming bleeding proceeded or 
worsened. 44 (68.8%) out of 64 patients kept 
experiencing dysfunctional bleeding and pain of 
abdominal allied with uterine fibroids in untreated 
controls and asked for another method of treatment. The 
adjustments in myomas volume between the exploratory 
and control gather significant statistically p value 0.044.   
Conclusion: Utilization of hormonal contraceptive low 
dose with progestin dominancy can prompt significant 
decrease in volume of myoma. 
Key words: Progestin Dominancy, Contraception, 
Growth, Regression, Myoma, Uterine Fibroids. 
INTRODUCTION 
Joined hormonal, estrogen-progestin, 
contraception offers numerous non prophylactic 
advantages. The ideal defensive and restorative 
impacts including some gynecological and non 
gynecological clutters are proving based and 
usually utilized in clinical practice. Among the 
most imperative non prophylactic advantages are 
the decreases of the danger of ovarian, endometrial 
& colorectal tumour, menorrhagia treatment, pre-
menstrual disorder, dysmenorrhea, inflammation of 
skin, endometriosis, vulgaris and uterine fibroids.[1] 
Something else, other hormonal preventative 
strategies offering a few advantages are 
additionally accessible (pills progestin only & the 
intra-uterine framework persistently discharging 
levonorgestrel).[2-3] 
Leiomyoma (uterine fibroid) is a benign, 
in uterus smooth muscle mesenchymal tumor 
mostly originated. It is generally frequent 
gynecological tumour that happens in over twenty 
percent of females over thirty years old and in 
thirty percent to forty percent of females between 
the ages of 40 years to 50 years. Leiomyoma is 
uncommon before spontaneously diminishes 
menarche and after menopause might be fading. In 
Czech Republic and additionally in other countries, 
the most regular hysterectomy sign is leiomyoma 
and performed 70% to 80% hysterectomies for 
menorrhagia and myoma.[4] 
In spite of its high occurrence, leiomyoma 
causal etiology stays unknown. There was an 
incontestable procedure of two steps at least. In 
start, physical change of one leiomyocyte happen 
and in instances of different fibroids, freely of the 
others. The hereditary inclination for various 
changes is recommended, in any case, the 
particular qualities have not been recognized. The 
2nd step contains cell multiplication under 
hyperestrogenic conditions. The myoma internal 
milieu is hyperestrogenous with high aromatase 
action and a high grouping of estrogen receptors. 
Other than estrogens, the accompanying other 
development factors are available: over-articulation 
of EGF (Epidermal Growth Factor) and IGFs 
(Insulin like Growth Factor) I and II. Anomalous 
vascularization is impacted by vascular endothelial 
development factor. Likewise an expanded 
grouping of a solid inhibitor of apoptosis, bcl-2 (B-
Cell Lymphoma), is watched.[5] 
As per number, myomas may be lone or 
various. Concerning confinement, myoma can be 
isolated into intramural, cervical, intraligamentous, 
subserousal, myoma nascens and submucosal, fig-
1.[6] As per histopathology, myomas can be 
separated into: cellular (atypical, proliferating) 
myoma (two – nine mitoses in ten microscopic 
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fields), benign myoma (with two or less in ten 
microscopic fields) and leiomyosarcoma (with in 
excess of ten mitosis in ten minuscule fields, 
cytological atypia and nearness of coagulation 
rot).[7] 
 
 
 
 
 
 
 
 
As per British investigation, 35% to 64% 
of females with leiomyomas experience the ill 
effects of useless uterine bleeding[8]; in some of 
them bringing about iron deficiency (anemia) 
35%.[2] Alternate side effects related with uterine 
fibroids are stomach and pelvic torment, 
dyspareunia, subfebrility, dysmenorrhea, issues 
emerging from weight on encompassing organs 
(urge incontinence, constipation, hydronephrosis, 
tenesmus, dysuria) and issues with fertility.[4] 
A few investigations theorize that 
hormonal contraception acts diversely on 
myometrial and on the fibromuscular tissue of 
leiomyoma. The principle advantage might be 
related with diminished expansion and expanded 
apoptosis of the tissues.[9] 
The purpose of this investigation was to 
report the progressions in uterine fibroids that were 
presented to the impact of low dose joined oral 
contraceptive with progestin-dominancy. 
MATERIALS AND METHODS  
This randomized controlled single blind 
prospective observational investigation was 
conducted at Sir Ganga Ram Hospital, Lahore from 
01.07.2017 to 31.07.2018. A sum of 258 females 
was enlisted in this investigation. An aggregate of 
194 patients in fertile age experiencing singular or 
numerous uterine fibroids were dealt with 
moderately with monophasic joined oral 
contraception contains 20mcg and 75mcg of 
ethinylestradiol and gestodene respectively. 114 
females gave side effects commonly associated 
with myoma. Dilatation & curettage for danger 
prohibition was performed before starting 
hormonal treatment just in instances of 
metrorrhagia. The joined oral contraception was 
managed in a regular twenty one day regimen with 
a delay of seven day. 
From the entire examination populace, the 
control gather was chosen by randomization; every 
4th was picked. The gathering comprised of 64 
patients of fertile age with single or different 
leiomyomas willing to be dealt with moderately. 
Non hormonal fake treatment pills were regulated 
by a similar twenty one day regimen. 
For a time of 2-years, watched the changes 
in the development of uterine myoma and clinical 
presentation. Thoshiba Nemio ultrasound gadget 
with vaginal test PVM 651VT of 6-MHz for 
location and estimation of fibroids was utilized. 
Prior to starting the investigation and at every three 
months following the principal 7-day stretch of 
menstrual dying, an ultrasound estimation & 
examination of fibroids was performed and 
enrolled the maximal measurement of the myoma. 
To evaluate changes over time statistical 
analysis Mann-Whitney Ran Sum Test was 
utilized, utilizing sigma stat 3.5. p value 0.05 was 
considered significant statistically. A written 
informed consent was also obtained from the 
enrolled patients. 
RESULTS  
During a considerable period of time, 
singular or different uterine fibroids of 8mm to 
65mm in distance across with different limitations 
were assessed. In 148 (76.3%) out of 194 patients 
treated with monophasic, relapse or no adjustments 
in development were enlisted and after that were 
followed up for a period of long time. The patients 
treated with joined oral contraception did not have 
any clinical issue. 50 (25.8%) patients without any 
adjustments in drug were lost from our records 
following 2-years, 98 (50.5%) proceeded for a long 
time wherein on a similar prescription. In 26 
(13.4%) out of 97-patients under monophasic 
joined pills, the development of fibroids and in 
addition issues like menorrhagia, pain of stomach, 
frailty and dysmenorrhea proceeded or expanded. 
In twenty patients extreme uterine bleeding was 
primary issue (300ml blood loss approximately), 6 
patients experienced pelvic and abdominal pain. 
They experienced task: in six cases myoma 
enucleation and in twenty cases laparoscopically 
helped vaginal hysterectomy was performed. In six 
of these cases, the absence of adequacy of the oral 
prophylactic pills can be clarified by poor patient 
consistence with the everyday endorsed dosing 
regimen. In another patient 1% who entered 
menopause following one year, bleeding ceased 
and myoma development, be that as it may, in spite 
 
Figure 1: 1: Myoma nascens; 
2: Cervical myoma; 3: 
Submucosal myoma; 
4:Submucousal pendulating 
myoma; 5:Intramural myoma; 6: 
Subserousal myoma; 7: 
Subserousal pendulating 
myoma; 8: Intraligamentous 
myoma. 
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of this reality, she demanded hysterectomy because 
of dread of cancer. In any case leiomyosarcoma 
histology was not found. Regardless of discoveries 
of moderate development in mm without clinical 
symptomatology in twelve cases & metrorrhagia 
because of sporadic hormonal treatment in six 
cases, every one of the 18 (9.3%) of these patients 
rejected prescribed operative treatment. 
64 patients of the control gather were 
followed up for a half year. Following a half year, 
16 (25%) of 64 females declined to experience 
more treatment due to abdominal pain and irregular 
bleeding. Another 28 (43.8%) females experiencing 
similar side effects finished follow-up of a year and 
after that left the examination. 20 (31.2%) patients 
achieved menopause aimed the season of the 
examination as well as neither clinical issue nor 
development of myoma was noted. 
We discovered significant statistically, p = 
0.044, changes in the myomas volume between the 
exploratory and control gathering. In the trial group 
directed with joined oral contraception for the time 
of two years, volumes of myoma significantly 
dropped from a mean estimation of 35.3mm to 
30.2mm at two years, p value 0.040. In the placebo 
group the volume of myomas increased slightly, 
however, the change was not significant 
statistically (35.3 – 36.8mm, p value 0.714 from 
mean estimation). 
DISCUSSION 
Uterine fibroids treatment is both surgical 
and pharmacological. The premise of 
pharmacological treatment is hormonal bar of 
endogenous steroidogenesis with GnRH 
(Gonadotropin Releasing Hormone) agonists 
(goserelin, triptorelin, buserelin and so forth), 
consolidated hormonal contraception with 
progestin dominancy, progestin only contraceptives 
and intra-uterine framework consistently 
discharging levonorgestrel. Monophasic 
consolidated contraceptives in ordinary twenty one 
days and also in ling cycle treatment, hinder the 
endogenous creation of steroids and balance out 
hormonal fixation.[10] In examination with 
Gonadotropin Discharging Hormone agonists, 
contraceptives are more affordable and have 
insignificant metabolic impacts. Progestin role is 
still controversial. EGF production stimulated by 
progesterone and EGF receptors expression 
stimulated through estrogens. Additionally, bcl-2 
expression stimulated by progesterone, 
notwithstanding, causes restraint of IGF-I and by 
IGF-II receptors down control obstructs the 
development of myoma.[5] Norethisterone and 
different progestin with leftover estrogenous 
movement ought not be utilized in light of the fact 
that they may empower the myomas development. 
Uterine fibroids, lessening in size, were seen with 
treatment of particular progesterone receptor 
modulators RU486 “mifepristone”. Aromatase 
inhibitors impact on myomas is under clinical 
examination. Danazol & gestrinone 
(antigonadotropins) ought not be utilized because 
of their serious lingering androgynous reactions, 
for example, gain body weight, hirsutism and break 
out skin, hepatotoxicity. Tamoxifen from the 
gathering of specific estrogen receptor modulators 
by incomplete estrogenous action may animate the 
myoma development.[4] 
As per the consequences of our controlled 
prospective single blind examine on a watched 
gathering of females treated with joined oral 
contraception with progestin dominancy containing 
20mcg and 75mcg of ethinylestradiol and 
gestodene respectively, patients of significant 
numbers experiencing issues related with uterine 
fibroids may somehow or another be effectively 
treated moderately; 150 (77.3%) out of 194. we 
watched not just reducing clinical issues related 
with uterine fibroids, for example, abdominal pain, 
menorrhagia and so on, but also a reduction in 
myomas size. In females evading surgery, 
preservationist treatment with hormonal 
contraceptives with progestin dominancy may be 
viewed as a reasonable option. 20 (31.2%) out of 
64 patients did not have clutters related with 
uterine fibroids in untreated controls. In 44 (22.7%) 
out of 194 females, failed therapy / treatment with 
monophasic contraception, in 6 because of poor 
consistence with every day pill use. 44 (68.8%) out 
of 64 females experienced typical problem and 
asked for other method of treatment. 
LNG IUS smothers expansion and 
investigates apoptosis of leiomyocytes. 
Proliferation is obstructed under insignificant 
centralizations of 10mcb per ML. A similar 
convergence of LNG altogether diminishes the 
IGFC I levels, bcl-2, survivin and builds enactment 
of caspase 3.[11] Syed etal in his investigation, LNG 
IUS failure 23.1% and low dose joined oral 
contraception failure 37.9% in fifty eight patients 
treated for fibroid related menorrhagia.[12] In our 
investigation, the monophasic pills disappointment 
rate containing 20mcg and 75mcg ethinylestradiol 
& gestodene respectively was just 22.7%. This 
might be clarified by the utilization of 
contraceptives with a low dosage of gestodene and 
ethinylestradiol whose gestational movement in 
vivo is one of the most grounded everything being 
equal. 
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In single blind investigation thinks about, 
the subject doesn’t know whether they are 
extremely treated or provided with fake treatment 
without viable compound. Be that as it may, there 
are few constraints and dangers of single blind 
preliminaries, for example, supposed 
experimenter’s inclination. The subjects may be 
deliberately or unknowingly impacted by 
specialists.  
 
 
 
Conclusion 
Monophasic consolidated contraception 
essentially hinders the endogenous creation of 
steroids and settles hormonal focuses. It may be 
considered as an appropriate option for females 
keeping away from agent treatment for different 
reasons. A vital necessity for traditionalist 
treatment is intermittent consistent ultrasound 
examinations for myoma identification. In 
instances of sudden unexpected development, the 
leiomyosarcoma origin must be resolved, moderate 
treatment quickly stopped and considered operative 
therapy. 
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